BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laszkowska M, Kim J, Faye AS, Joelson AM, Ingram M, Truong H, Silver ER, May B, Greendyke WG, Zucker J, Lebwohl B, Hur C, Freedberg DE. Prevalence of Clostridioides difficile and Other Gastrointestinal Pathogens in Patients with COVID-19. Dig Dis Sci 2021. [PMID: 33479861 DOI: 10.1007/s10620-020-06760-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Filik L. C. difficile in COVID-19 Patients: Is It a Colonization Issue? Dig Dis Sci 2021. [PMID: 33982220 DOI: 10.1007/s10620-021-06959-7] [Reference Citation Analysis]
2 Ondrikova N, Clough HE, Douglas A, Iturriza-Gomara M, Larkin L, Vivancos R, Harris JP, Cunliffe NA. Differential impact of the COVID-19 pandemic on laboratory reporting of norovirus and Campylobacter in England: A modelling approach. PLoS One 2021;16:e0256638. [PMID: 34432849 DOI: 10.1371/journal.pone.0256638] [Reference Citation Analysis]
3 Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211016248. [PMID: 34093740 DOI: 10.1177/17562848211016248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cojocariu C, Girleanu I, Trifan A, Olteanu A, Muzica CM, Huiban L, Chiriac S, Singeap AM, Cuciureanu T, Sfarti C, Stanciu C. Did the severe acute respiratory syndrome-coronavirus 2 pandemic cause an endemic Clostridium difficile infection? World J Clin Cases 2021; 9(33): 10180-10188 [PMID: 34904088 DOI: 10.12998/wjcc.v9.i33.10180] [Reference Citation Analysis]
5 Maricuto AL, Velásquez VL, Pineda J, Flora-Noda DM, Rodríguez I, Rodríguez-Inés CA, Noya-González ÓO, Contreras R, Omaña-Ávila ÓD, Escalante-Pérez IA, Camejo-Ávila NA, Kuffaty-Akkou NA, Carrión-Nessi FS, Carballo M, Landaeta ME, Forero-Peña DA. Amoebic liver abscess in a COVID-19 patient: a case report. BMC Infect Dis 2021;21:1134. [PMID: 34736397 DOI: 10.1186/s12879-021-06819-9] [Reference Citation Analysis]
6 Kochar BD, Cai W, Ananthakrishnan AN. Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty. Dig Dis Sci 2021. [PMID: 33932198 DOI: 10.1007/s10620-021-06990-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chhibber-Goel J, Gopinathan S, Sharma A. Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections? Gut Pathog 2021;13:14. [PMID: 33632296 DOI: 10.1186/s13099-021-00407-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Granata G, Petrosillo N, Al Moghazi S, Caraffa E, Puro V, Tillotson G, Cataldo MA. The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis. Anaerobe 2021;:102484. [PMID: 34843959 DOI: 10.1016/j.anaerobe.2021.102484] [Reference Citation Analysis]
9 Kullar R, Johnson S, McFarland LV, Goldstein EJC. Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use. Antibiotics (Basel) 2021;10:408. [PMID: 33918619 DOI: 10.3390/antibiotics10040408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ahn SY, Park JY, Lim IS, Chae SA, Yun SW, Lee NM, Kim SY, Choi BS, Yi DY. Changes in the Occurrence of Gastrointestinal Infections after COVID-19 in Korea. J Korean Med Sci 2021;36:e180. [PMID: 34155841 DOI: 10.3346/jkms.2021.36.e180] [Reference Citation Analysis]